PTCT – PTC Therapeutics Inc
PTC Therapeutics, Inc.PTCT
$46.39Name : PTC Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,676,732,160.00
EPSttm : 6.51
PTC Therapeutics, Inc.
$46.39
0.83%$0.38Float Short %
6.49
Margin Of Safety %
47
Put/Call OI Ratio
1
EPS Next Q Diff
-9.85
EPS Last/This Y
12.22
EPS This/Next Y
-9.42
Price
46.39
Target Price
61.13
Analyst Recom
1.94
Performance Q
-4.62
Relative Volume
0.93
Beta
0.5
Ticker: PTCT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | PTCT | 45.06 | 1.67 | 0.00 | 7656 |
| 2025-04-15 | PTCT | 46.96 | 1.67 | 0.00 | 7660 |
| 2025-04-16 | PTCT | 46.42 | 1.66 | 0.04 | 7666 |
| 2025-04-17 | PTCT | 47.38 | 1.53 | 0.02 | 7507 |
| 2025-04-18 | PTCT | 47.39 | 1.53 | 0.04 | 7507 |
| 2025-04-21 | PTCT | 48.17 | 0.70 | 0.02 | 11415 |
| 2025-04-22 | PTCT | 48.19 | 0.54 | 0.92 | 13387 |
| 2025-04-23 | PTCT | 50.02 | 0.62 | 1.92 | 17611 |
| 2025-04-24 | PTCT | 49.53 | 0.62 | 0.40 | 17699 |
| 2025-04-25 | PTCT | 49.53 | 0.62285348922178 | 0.14184397163121 | 17767 |
| 2025-04-28 | PTCT | 49.76 | 0.61740543468448 | 0.97892347600519 | 17916 |
| 2025-04-29 | PTCT | 49.52 | 0.70 | 0.12 | 23943 |
| 2025-04-30 | PTCT | 49.85 | 0.69 | 0.72 | 24083 |
| 2025-05-01 | PTCT | 49.45 | 0.70 | 1.94 | 24150 |
| 2025-05-02 | PTCT | 49.9 | 0.70 | 1.38 | 24179 |
| 2025-05-05 | PTCT | 40.65 | 0.70 | 0.37 | 24359 |
| 2025-05-06 | PTCT | 35.8 | 0.76 | 1.51 | 24351 |
| 2025-05-07 | PTCT | 40.74 | 0.97 | 0.06 | 27849 |
| 2025-05-08 | PTCT | 42.54 | 1.01 | 0.03 | 27450 |
| 2025-05-09 | PTCT | 44.18 | 1.02 | 0.42 | 27257 |
| 2025-05-12 | PTCT | 46 | 1.02 | 0.01 | 27227 |
| 2025-05-13 | PTCT | 46.37 | 1.00 | 2.08 | 27465 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | PTCT | 45.08 | 41.3 | 1208.7 | -3.36 |
| 2025-04-15 | PTCT | 46.94 | 41.3 | 1203.9 | -3.36 |
| 2025-04-16 | PTCT | 46.41 | 41.3 | 1166.4 | -3.36 |
| 2025-04-17 | PTCT | 47.39 | 41.3 | 1189.7 | -3.36 |
| 2025-04-18 | PTCT | 47.39 | 41.3 | 1174.5 | -3.36 |
| 2025-04-21 | PTCT | 48.17 | 41.3 | 1186.4 | -3.36 |
| 2025-04-22 | PTCT | 48.19 | 41.3 | 1174.6 | -3.36 |
| 2025-04-23 | PTCT | 49.95 | 41.3 | 1200.9 | -3.36 |
| 2025-04-24 | PTCT | 49.54 | 41.3 | 1168.6 | -3.36 |
| 2025-04-25 | PTCT | 49.53 | 41.3 | 1174.1 | -3.36 |
| 2025-04-28 | PTCT | 49.76 | 41.3 | 1177.9 | -3.36 |
| 2025-04-29 | PTCT | 49.52 | 41.3 | 1171.0 | -3.36 |
| 2025-04-30 | PTCT | 49.84 | 41.3 | 1179.2 | -3.36 |
| 2025-05-01 | PTCT | 49.52 | 41.3 | 1169.8 | -3.36 |
| 2025-05-02 | PTCT | 49.95 | 41.3 | 1180.8 | -3.36 |
| 2025-05-05 | PTCT | 40.65 | 41.3 | 1038.1 | -3.36 |
| 2025-05-06 | PTCT | 36.16 | 41.3 | 1098.1 | -3.36 |
| 2025-05-07 | PTCT | 40.76 | 41.3 | 1258.8 | -3.36 |
| 2025-05-08 | PTCT | 42.51 | 17.3 | 251.8 | -3.52 |
| 2025-05-09 | PTCT | 44.23 | 0.0 | 234.1 | 7.49 |
| 2025-05-12 | PTCT | 46.01 | 0.0 | 233.7 | 7.49 |
| 2025-05-13 | PTCT | 46.39 | 0.0 | 172.1 | 7.49 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | PTCT | -15.25 | -1.67 | 7.05 |
| 2025-04-15 | PTCT | -15.25 | -1.67 | 7.05 |
| 2025-04-16 | PTCT | -15.25 | -1.67 | 7.05 |
| 2025-04-17 | PTCT | -15.25 | -1.67 | 7.05 |
| 2025-04-18 | PTCT | -15.25 | -1.67 | 7.05 |
| 2025-04-21 | PTCT | -15.25 | -1.66 | 7.05 |
| 2025-04-22 | PTCT | -15.25 | -1.66 | 7.05 |
| 2025-04-23 | PTCT | -15.25 | -1.66 | 7.05 |
| 2025-04-24 | PTCT | -15.25 | -1.66 | 7.05 |
| 2025-04-25 | PTCT | -15.35 | -1.66 | 7.05 |
| 2025-04-28 | PTCT | -15.35 | -3.96 | 7.13 |
| 2025-04-29 | PTCT | -15.35 | -3.96 | 7.13 |
| 2025-04-30 | PTCT | -15.35 | -3.96 | 7.13 |
| 2025-05-01 | PTCT | -15.35 | -3.96 | 7.13 |
| 2025-05-02 | PTCT | -15.35 | -3.96 | 7.13 |
| 2025-05-05 | PTCT | -15.35 | -3.81 | 7.13 |
| 2025-05-06 | PTCT | -15.35 | -3.81 | 7.13 |
| 2025-05-07 | PTCT | -15.35 | -3.81 | 7.13 |
| 2025-05-08 | PTCT | -15.35 | -3.81 | 7.13 |
| 2025-05-09 | PTCT | -15.29 | -3.81 | 7.10 |
| 2025-05-12 | PTCT | -15.29 | -1.75 | 6.49 |
| 2025-05-13 | PTCT | -15.29 | -1.75 | 6.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
10.04
Avg. EPS Est. Current Quarter
-1.27
Avg. EPS Est. Next Quarter
0.19
Insider Transactions
-15.29
Institutional Transactions
-1.75
Beta
0.5
Average Sales Estimate Current Quarter
173
Average Sales Estimate Next Quarter
196
Fair Value
68.26
Quality Score
94
Growth Score
44
Sentiment Score
79
Actual DrawDown %
34.5
Max Drawdown 5-Year %
-73.8
Target Price
61.13
P/E
7.12
Forward P/E
PEG
0.13
P/S
2.07
P/B
P/Free Cash Flow
5.31
EPS
6.51
Average EPS Est. Cur. Y
7.49
EPS Next Y. (Est.)
-1.93
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
33.55
Relative Volume
0.93
Return on Equity vs Sector %
-343.9
Return on Equity vs Industry %
-327
EPS 1 7Days Diff
10.8
EPS 1 30Days Diff
10.85
EBIT Estimation
172.1
PTC Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 939
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
stock quote shares PTCT – PTC Therapeutics Inc Stock Price stock today
news today PTCT – PTC Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTCT – PTC Therapeutics Inc yahoo finance google finance
stock history PTCT – PTC Therapeutics Inc invest stock market
stock prices PTCT premarket after hours
ticker PTCT fair value insiders trading